In a three-stage genome-wide association study among East Asian women including 22,780 cases and 24,181 controls, we identified 3 genetic loci newly associated with breast cancer risk, including rs4951011 at 1q32.1 (in intron 2 of the ZC3H11A gene; P = 8.82 × 10 −9 ), rs10474352 at 5q14.3 (near the ARRDC3 gene; P = 1.67 × 10 −9 ) and rs2290203 at 15q26.1 (in intron 14 of the PRC1 gene; P = 4.25 × 10 −8 ). We replicated these associations in 16,003 cases and 41,335 controls of European ancestry (P = 0.030, 0.004 and 0.010, respectively). Data from the ENCODE Project suggest that variants rs4951011 and rs10474352 might be located in an enhancer region and transcription factor binding sites, respectively. This study provides additional insights into the genetics and biology of breast cancer.
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Breast cancer is one of the most common malignancies among women worldwide. Genetic factors have a substantial role in breast cancer etiology 1, 2 . Thus far, genome-wide association studies (GWAS) have identified approximately 75 genetic loci associated with breast cancer risk [2] [3] [4] [5] . With the exception of the studies we have conducted among East Asian women [6] [7] [8] [9] and one study conducted among women of African ancestry 10 , all other published GWAS have been conducted among women of European ancestry. Genetic risk variants identified thus far from GWAS explain only about 10% of familial risk for breast cancer in East Asian women 3 . Given the differences in genetic architecture and environmental exposures for women of European and East Asian ancestry, additional GWAS need to be conducted among East Asian women to study the genetic basis of breast cancer risk.
The current study was conducted as part of the Asia Breast Cancer Consortium (ABCC) to search for additional susceptibility loci for breast cancer. Included in this study are data obtained from 22,780 breast cancer cases and 24,181 controls who were recruited in 14 studies conducted in multiple Asian countries (Supplementary Table 1 ). The discovery stage (stage 1) included 2 GWAS in which 5, 285 Chinese women (SBCGS-1) and 4,777 Korean women (SeBCS1) were scanned primarily using Affymetrix Genome-Wide Human SNP Array 6.0, which consists of 906,602 SNPs. After applying quality control filters described previously 6,9,11 , 5,152 Chinese women (2,867 cases and 2,285 controls; 677,157 SNPs) and 4,298 Korean women (2,246 cases and 2,052 controls; 555,117 SNPs) remained in the current analysis. Imputation was conducted for each study following the MACH algorithm 12 using HapMap 2 release 22 CHB (Han Chinese in Beijing, China) and JPT (Japanese in Tokyo, Japan) data (2,416,663 SNPs) as the reference. Only SNPs with a high imputation quality score (RSQR ≥ 0.50) were analyzed for associations with breast cancer risk. In the analyses of data from Chinese and Korean women, a total of 1,930,412 and 1,907,146 SNPs, respectively, were included. A meta-analysis of these GWAS data was conducted using a fixedeffects, inverse variance meta-analysis with the METAL program 13 . There was little evidence of inflation in the association test statistics for the studies included in stage 1 (genomic inflation factors (λ): λ = 1.0426 for SBCGS-1, λ = 1.0431 for SeBCS1 and λ = 1.0499 for both studies combined; Supplementary Fig. 1) . When scaled to a study of 1,000 cases and 1,000 controls, λ 1,000 values were 1.02, 1.02 and 1.01, respectively.
To select SNPs for stage 2 replication, we used the following criteria: (i) association P < 0.05 in the stage 1 meta-analysis results; (ii) the Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1 same direction of association in both stage 1 studies; (iii) no heterogeneity observed between the two stage 1 studies (P > 0.05 and I 2 < 25%); (iv) an imputation score of RSQR > 0.5 in both stage 1 studies; (v) a minor allele frequency (MAF) of >0.05 in both stage 1 studies; and (vi) lack of strong LD (r 2 < 0.5) with any of the known breast cancer susceptibility loci or any SNPs for which we had previously found evidence of association 3, [6] [7] [8] [9] . For SNPs that met the above criteria but were in LD (r 2 > 0.5) with each other, we selected only one SNP for replication. A total of 4,598 SNPs were selected, and assays for 4,071 SNPs were successfully designed using Illumina Infinium assays as part of a large-scale genotyping effort. Of the 4,071 SNPs, 3,850 were successfully genotyped in an independent set of 3,944 cases and 3,980 controls selected from the Shanghai studies (SBCGS-2). After quality control exclusions, 3,678 SNPs were included in the analyses of 3,472 cases and 3,595 controls.
For stage 3, the top 50 SNPs were selected for further replication in an independent set of 14,195 cases and 16,249 controls from 10 studies participating in ABCC on the basis of the following criteria: (i) association P < 0.005 in the meta-analysis of stage 1 and 2 data and (ii) the same direction of association in both stages 1 and 2. Of the 50 SNPs evaluated in stage 3, 11 showed an association with breast cancer risk at P < 0.05 (Supplementary Table 2 ). Combined analyses of data from all three stages identified three SNPs that were associated with breast cancer risk at the genome-wide significance level (P < 5.0 × 10 −8 ): rs4951011 at 1q32.1, odds ratio (OR) = 1.09, P = 8.82 × 10 −9 ; rs10474352 at 5q14.3, OR = 1.09, P = 1.67 × 10 −9 ; and rs2290203 at 15q26.1, OR = 1.08, P = 4.25 × 10 −8 ( Table 1) . The association between breast cancer risk and each of these three SNPs was consistent across the studies included in ABCC (Fig. 1) , and none of the tests for heterogeneity gave statistically significant results (P > 0.05) ( Table 1) . No significant heterogeneity was found for the association of these three SNPs with breast cancer risk among Chinese, Japanese or Korean women (Supplementary Table 3 ). One additional SNP showed an association with breast cancer risk with a P value near the conventional GWAS significance level (rs11082321 at 18q11.2, OR = 1.08, P = 6.77 × 10 −7 ) (Supplementary Table 2 ).
The associations of SNPs rs10474352 and rs2290203 appeared to be stronger for estrogen receptor (ER)-positive breast cancer than for ER-negative breast cancer, and the heterogeneity test was of borderline significance for rs10474352 (P = 0.085) (Supplementary Table 4 ). The associations of rs4951011 with breast cancer risk were similar for ER-positive and ER-negative breast cancer.
We evaluated the three newly identified risk variants for associations with breast cancer risk in women of European ancestry using data from 16,003 cases and 41,335 controls from 12 breast cancer GWAS and included in the DRIVE GAME-ON Consortium. SNPs rs4951011, rs10474352 and rs2290203 were all associated with breast cancer risk in women of European ancestry at P < 0.05 with the same direction of association as observed in East Asian women (Supplementary Table 5 ). However, the strength of the associations was weaker in women of European ancestry than in women of East Asian ancestry, and the frequencies of the risk alleles were quite different in these two populations. l e t t e r s npg l e t t e r s
We evaluated and annotated putative functional variants and candidate genes in each of the three newly identified loci using data from the Encyclopedia of DNA Elements (ENCODE) 14 Project, The Cancer Genome Atlas (TCGA) breast cancer project 15 and expression quantitative trait locus (eQTL) databases 16 as well as RegulomeDB 17 and HaploReg v2 (ref. 18 ). We summarize the results below for each locus.
SNP rs10474352 is located on 5q14.3, 53,078 bp upstream of the ARRDC3 gene (Fig. 2b) . The ARRDC3 gene is a member of the arrestin gene family and is suspected of having a role in breast cancer development. A gene cluster at 5q11-q23 that includes ARRDC3 was found to be deleted in 17% of breast cancer tumor tissues 19 . Upregulation of the ARRDC3 gene in a breast cancer cell line has been shown to repress cell proliferation, migration, invasion and in vivo tumorigenesis 20 . We evaluated ARRDC3 gene expression in 87 breast cancer cases included in TCGA. The expression level of the ARRDC3 gene was significantly lower in tumor tissue than in adjacent normal tissue (P = 1.88 × 10 −18 ) (Supplementary Table 6 ). This finding is consistent with a previous study showing that expression levels of the ARRDC3 gene were lower in breast tumor tissue in comparison to normal tissue and in metastatic tumor tissue in comparison to primary tumor tissue 20 . Furthermore, lower ARRDC3 expression in tumor tissue has been associated with poorer disease-free survival in individuals with breast cancer 20 . A search of RegulomeDB 17 and HaploReg 18 indicated that rs10474352 might be located in predicted AP-1and VDR motifs (Supplementary Table 7) , suggesting a potential regulatory role. We evaluated whether SNPs in this locus act as cis-eQTLs for other genes by analyzing TCGA breast cancer data. Our analysis showed no evidence that this SNP or its correlated SNPs were cis-eQTLs for any genes in this locus. Recently, a SNP located ~596 kb upstream of the ARRDC3 gene, rs421379, was found to be associated with prognosis for early-onset breast cancer in a GWAS 21 . However, rs421379 is not in LD with rs10474352 (r 2 = 0 in both ASN (Asian) and CEU (Utah residents of Northern and Western European ancestry) data), the SNP in close proximity to ARRDC3 that was identified in our study. Furthermore, in our study, rs421379 had a low MAF (0.03-0.04) and was not associated with breast cancer risk (P = 0.2484 in stage 1).
SNP rs2290203 is located in intron 14 of the PRC1 gene (NM_ 003981) at 15q26.1 (Fig. 2c) . This gene encodes the protein regulator of cytokinesis 1 (PRC1) protein, which is involved in cytokinesis and is a substrate for several cyclin-dependent kinases 22 . The PRC1 gene is downregulated by p53 in MCF-7 and T47D breast cancer cells 23 . Interestingly, the PRC1 gene is included in a five-gene expression signature that predicted prognosis for individuals with breast cancer in a recent study 24 . The expression level of the PRC1 gene was significantly higher in tumor tissue than in adjacent normal tissue (P = 4.62 × 10 −30 ) among breast cancer cases included in TCGA (Supplementary Table 6 ). Our cis-eQTL analysis using TCGA data showed no association of rs2290203 with PRC1 gene expression but did show a correlation with expression of the RCCD1 gene, which is 5,712 bp upstream of rs2290203. An eQTL analysis of human monocytes has also indicated that rs2290203 is a cis-eQTL for the RCCD1gene 16 . In our study, the rs2290203 risk allele (G) was associated with lower RCCD1 expression in both tumor (P = 3.6 × 10 −4 ) and adjacent normal tissue (P = 0.007) (Supplementary Fig. 2) . However, these associations were no longer statistically significant after adjusting for the most significant cis-eQTL SNPs (rs4544218 for tumor tissue; rs59278520 for normal tissue), which are in strong LD with rs2290203 ( Supplementary  Fig. 3 ). Variant rs4544218 was not associated with breast cancer risk (P = 0.8925), and rs59278520 was marginally associated with breast npg l e t t e r s cancer risk (P = 0.0518) in the SBCGS-1 stage 1 samples. The function of the RCCD1 gene is unknown. SNP rs4951011 is located in intron 2 of the ZC3H11A gene (encoding zinc finger CCCH domain-containing protein 11A) (NM_014827) at 1q32.1 (Fig. 2a) and the 5′ UTR of the ZBED6 gene (encoding zinc finger BED domain-containing protein 6) (NM_001174108) (not shown). The ZBED6 protein has recently been recognized as a novel transcription factor in placental mammals 25 . The function of the ZC3H11A gene is not clear. ChromHMM annotation using human mammary epithelial cell (HMEC) data from ENCODE suggests that rs4951011 might be located in a strong enhancer region marked by peaks of several active histone methylation modifications (monomethylation of histone H3 at lysine 4 (H3K4me1), trimethylation of histone H3 at lysine 4 (H3K4me3), acetylation of histone H3 at lysine 9 (H3K9ac) and acetylation of histone H3 at lysine 27 (H3K27ac)). A search of RegulomeDB and HaploReg indicated that rs4951011 might be located in a predicted HNF1 motif and map to a DNase I hypersensitivity site in the MCF-7 breast cancer cell line (Supplementary Table 7) . Expression levels of the ZC3H11A gene were significantly higher in breast tumor tissue than in adjacent normal tissue (P = 0.0049) in TCGA data (Supplementary Table 6 ). Analyses using TCGA data showed no evidence that this SNP or other SNPs correlated with it are cis-eQTLs for any genes in this locus. Recently, SNP rs4245739 in the MDM4 gene, ~752 kb downstream of rs4951011 (r 2 = 0 in both ASN and CEU data), was associated with ER-negative breast cancer risk 5 . In our study, rs4245739 had a low MAF (0.03-0.05) and was not associated with breast cancer risk (P = 0.1861 in stage 1).
In summary, our large GWAS conducted among East Asian women identified three new breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1 and suggested a possible association with a fourth locus at 18q11.2. The associations of these loci with breast cancer risk might be mediated through the regulation of cell growth control, tumor cell migration and invasion, or metastasis. Further studies of possible mechanisms through which these loci and genes are involved in breast tumorigenesis are warranted. Results from this study provide additional insights into the genetics and biology of breast cancer.
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METhODs
Methods and any associated references are available in the online version of the paper. annotation using HaploReg v2 (see URLs) 18 , a tool for exploring the annotations of the noncoding genome at variants on haplotype blocks. eQTL analysis. We used TCGA breast cancer data (Supplementary Note) to perform an eQTL analysis for normal and tumor tissue samples separately. Detailed descriptions of the eQTL analysis are presented in the Supplementary Note. We focused only on SNPs and genes located within the 1-Mb regions flanking the three newly identified risk loci to identify cis-eQTLs. A significance threshold P value of <0.01 was used to identify candidate cis-eQTLs.
Differential gene expression analysis. To identify differentially expressed genes located in the three identified risk loci, we analyzed data from a total of 87 pairs of tumor-normal breast tissue samples included in TCGA (Supplementary Note). Detailed descriptions of the differential gene expression analysis are presented in the Supplementary Note.
